GSK has joined forces with Vodafone for an innovative partnership that aims to transform access to medicines and vaccines in developing countries by harnessing the power of mobile phone technology.
Despite major advances in the funding and availability of vaccines worldwide, up to one in five children still do not receive basic immunisation. The widespread availability of mobile phones in Africa offers an opportunity to create innovative and cost-effective solutions that address barriers to universal vaccination.
The initial focus of the new partnership is a one-year pilot vaccination project in Mozambique, in collaboration with the country’s Ministry of Health. This aims to establish if mobile technology solutions could increase the proportion of children covered by vaccination in Mozambique by an additional 5-10% in three key areas:
The pilot commenced in 2013 with 10 clinics, and will eventually include up to 100 clinics. It will be independently monitored by Harvard University to assess its impact, effectiveness and cost benefits. To ensure open access, the platform will be available to caregivers across any mobile network and can be used to increase take-up of any selected vaccine.
If successful, the project will create a model that can be replicated throughout Mozambique and eventually across Africa to reach thousands more children with life-saving vaccination.
|Location||Mozambique, Southern Africa|